Full Press Release Details
Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a
generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse
events related to study drug in diabetes and 0% study discontinuation rate due to adverse events in obesity
Phase 2a data from first study in type 2 diabetes mellitus (T2DM) demonstrate significant reductions in hemoglobin A1c (HbA1c) and
2a data from obesity cohort demonstrate significant reduction in weight at 8 weeks; full 12-week obesity data expected in second quarter
2024 with Phase 2b study initiation on track for second half 2024
includes results from Japanese bridging study and findings from 6- and 9-month toxicology studies demonstrating encouraging safety to
support advancing into Phase 2b development
conference call today at 8:30 a.m. ET
FRANCISCO - December 18, 2023 - Structure Therapeutics Inc. (NASDAQ: GPCR),
a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary
diseases, today provided a comprehensive development program update for its highly selective oral GLP-1 receptor agonist, GSBR-1290.
"We are pleased that we have achieved
the objectives of our first Phase 2a clinical trial of GSBR-1290 in T2DM patients which were to demonstrate favorable safety, tolerability
and efficacy results and guide our plans to further optimize the already encouraging performance of GSBR-1290," said Raymond Stevens,
Ph.D., Founder and CEO of Structure. "Our data demonstrated that once-daily GSBR-1290 has the potential to be a best-in-class compound
and a backbone for future combinations that could address large cardiometabolic indications."
"GSBR-1290 has demonstrated proof
of concept in individuals with both obesity and T2DM, with clear effects on both weight loss and HbA1c that has the potential to increase
with longer duration of treatment," said David D'Alessio, M.D., Chief of the Division of Endocrinology and Metabolism at
Duke University. "The unmet medical need for both T2DM and chronic weight management continues to be very large, and the GLP-1
receptor is a target with considerable potential. Safe and effective oral small molecule GLP-1 receptor agonists would be a significant
advance in that they could expand access for many patients for whom this is not now possible."
Phase 2a Study in Diabetes and Obesity
The randomized, double-blind, 12-week
placebo-controlled Phase 2a clinical trial has enrolled a total of 94 participants to date, including 60 participants randomized to GSBR-1290.
The T2DM cohort enrolled 54 participants, randomized to GSBR-1290 45 mg (n=10) or 90 mg (n=26), or placebo (n=18), dosed once daily.
The obesity cohort initially enrolled 40 individuals randomized to GSBR-1290 120 mg (n=24) or placebo (n=16), once-daily. An additional
24 participants are currently being enrolled in the obesity arm as previously announced and will also be randomized 3:2 to GSBR-1290
The primary endpoint of the Phase 2a
study is safety and tolerability of GSBR-1290. Key secondary endpoints include reduction in weight for both cohorts, as well as reduction
in HbA1c for the T2DM cohort.
Safety and Tolerability Results
GSBR-1290 demonstrated encouraging safety
and tolerability following repeated, daily dosing for all doses studied (up to 120 mg) in the obesity and T2DM cohorts.
Table 1: Summary of Treatment Emergent
Adverse Events (TEAEs)
| Phase 2a TDM Cohort (12-week data) | Phase 2a Obesity Cohort (12-week interim data) | ||||
| Event, N (%) | GSBR-1290 45 mg (n=10) | GSBR-1290 90 mg (n=26) | Placebo (n=18) | GSBR-1290 120 mg (n=24) | Placebo (n=16) |
| Any TEAE | 10 (100) | 25 (96.2) | 8 (44.4) | 23 (95.8) | 11 (68.8) |
| Any TEAE by maximum severity | |||||
| Mild | 2 (20) | 6 (23.1) | 6 (33.3) | 6 (25) | 9 (56.3) |
| Moderate | 7 (70) | 17 (65.4) | 2 (11.1) | 17 (70.8) | 2 (12.5) |
| Severe | 0 | 2 (7.7) | 0 | 0 | 0 |
| Any SAEs | 1 (10) | 1 (3.8) | 0 | 0 | 0 |
| Any SAEs related to study drug | 0 | 0 | 0 | 0 | 0 |
GSBR-1290 demonstrated clinically meaningful
activity in both T2DM and obesity cohorts.
Table 2: Diabetes cohort least square
means difference (LSM) change in HbA1C from baseline to 12 weeks (%)
| GSBR-1290 45 mg (n=10) | GSBR-1290 90 mg (n=26) | Placebo (n=18) | |
| LSM HbA1C change from baseline (%) | -0.79 | -0.84 | 0.18 |
| % HbA1C change placebo-adjusted (LSM, 95% confidence interval (CI)) | -1.01 (-1.73, -0.29) | -1.02 (-1.59, -0.44) | |
| P-value vs. placebo | p= 0.008 | p= 0.001 |
* LSM, CI and p value
from Mixed Model for Repeated Measures
Table 3: Diabetes cohort LSM change
in weight from baseline (%)
| GSBR-1290 45 mg (n=10) | GSBR-1290 90 mg (n=26) | Placebo (n=18) | |
| LSM weight change from baseline (%) | -3.32 | -3.22 | 0.04 |
| % weight change placebo-adjusted (LSM, 95% CI) | -3.51 (-5.58, -1.43) | -3.26 (-5.17, -1.36) | - |
| P-value vs. placebo | p= 0.0019 | p= 0.0013 | - |
* LSM, CI and p value
from Mixed Model for Repeated Measures
Table 4: Obesity Cohort LSM change in
weight from baseline (%) 8-week interim results
| GSBR-1290 120 mg (n=24) | Placebo (n=16) | |
| LSM weight change from baseline (%) | -5.55 | -0.82 |
| % weight change placebo-adjusted (LSM, 90% CI) | -4.74 (-6.74, -3.10) | |
| P-value vs. placebo | p< 0.0001 |
* LSM, CI and p value
from Mixed Model for Repeated Measures
Results from Phase 1 Japanese Bridging
The 4-week Phase 1 Japanese ethnobridging
study included healthy lean Japanese participants randomized to GSBR-1290 (n=9) and placebo (n=3), and healthy lean non-Japanese participants
receiving GSBR-1290 (n=6). GSBR-1290 demonstrated a substantial weight reduction in Japanese participants (-3.91% on GSBR-1290 vs -1.67%
placebo) and in non-Japanese participants (-5.13% not placebo-adjusted), with no discontinuations or dose reductions, and no SAEs. These
data will be used for regulatory interactions in Japan in preparation for potential future global studies of GSBR-1290.
Results from 6- and 9-Month Toxicology
preparation for Phase 2b development with longer durations of treatment, Structure has completed 6-month (rodent) and 9-month (non-human
primate) toxicology studies to evaluate the safety of GSBR-1290. No major findings were observed in either study, with no test article-related
changes observed in the liver, including ALT/AST, at all doses, and a >100 fold safety window
at the 120 mg therapeutic dose.
GSBR-1290 Next Steps
Full 12-week results from the Phase
2a obesity cohort (n=64), including data from the additional 24 participants currently being enrolled, are expected in the second quarter
Structure plans to initiate a Phase
2b obesity study of GSBR-1290 in the second half of 2024. The study is planned to include at least 275 individuals across the United
States and Europe and will include multiple modified dose titration regimens to optimize efficacy and tolerability. An additional Phase
2 study in T2DM is also planned for the second half of 2024 to optimize the efficacy and tolerability of GSBR-1290 in this patient population.
The ongoing formulation bridging and
titration optimization study is evaluating capsule versus tablet pharmacokinetics (PK) and exploring different titration regimens. This
study has completed enrollment (n=54), and data are expected in the second quarter of 2024. Pending supportive data from this bridging
study, the tablet formulation would be used in future GSBR-1290 studies starting with the Phase 2b studies.
Conference Call and Webcast Information
will host a conference call and webcast today, December 18, 2023 at 8:30 a.m. Eastern Time. A live webcast of the call will
be available on the Investor Relations page of Structure's website at https://ir.structuretx.com/events-presentations/events.
To access the call by phone, participants should visit this link (registration link) to receive
dial-in details. The webcast will be made available for replay on the company's website beginning approximately two hours after the live
event. The replay of the webcast will be available for 90 days.
About GSBR-1290 and Structure's
Oral Metabolic Franchise
GSBR-1290 is an orally-available, small
molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor, a validated drug target for the treatment of type 2 diabetes and obesity.
GSBR-1290 was designed through the company's structure-based drug discovery platform to be a biased GPCR agonist, which selectively
activates the G-protein signaling pathway. Beyond GSBR-1290, Structure is developing next generation combination GLP-1R candidates together
with GIP, amylin, glucagon and apelin.
About Structure Therapeutics
Therapeutics is a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative oral treatments for
chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based
drug discovery platform, the company has established a scientifically-driven, GPCR-targeted pipeline, featuring two wholly-owned proprietary
clinical-stage small molecule compounds. These compounds are designed to surpass the limitations of traditional biologic and peptide
therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Forward Looking Statements
press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be
deemed forward-looking statements, including, without limitation, statements concerning the Company's future plans and prospects;